Literature DB >> 5044816

Disposition of tritium-labeled spirolactones in the dog.

W Sadée, S Riegelman, S C Jones.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5044816     DOI: 10.1002/jps.2600610721

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  6 in total

Review 1.  Diuretics: mechanism of action and clinical application.

Authors:  D L Davies; G M Wilson
Journal:  Drugs       Date:  1975       Impact factor: 9.546

2.  Canrenoate disposition in dogs. Tissue distribution and elimination.

Authors:  J Kuhlmann; V Kötter; N Rietbrock
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-06       Impact factor: 3.000

3.  [Relative bioavailability in man of 2 pharmaceutical forms of canrenone].

Authors:  F Bressolle; J Bres; A Faure; M C Pistre
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Jul-Sep       Impact factor: 2.441

4.  Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats.

Authors:  W Sadée; U Abshagen; C Finn; N Rietbrock
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

5.  Difference in metabolic profile of potassium canrenoate and spironolactone in the rat: mutagenic metabolites unique to potassium canrenoate.

Authors:  C S Cook; C L Hauswald; G L Schoenhard; C E Piper; A Patel; F M Radzialowski; J D Hribar; W Aksamit; P Finnegan; R H Bible
Journal:  Arch Toxicol       Date:  1988-01       Impact factor: 5.153

Review 6.  Role of mineralocorticoid receptor antagonists in cardiovascular disease.

Authors:  Carlos M Ferrario; Ernesto L Schiffrin
Journal:  Circ Res       Date:  2015-01-02       Impact factor: 17.367

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.